Here is the design of a clinical trial:

Official Title: Transforaminal Epidural Injection in Acute Sciatica

Included conditions:
- Sciatica
- Sciatica Due to Intervertebral Disc Disorder
- Sciatic Radiculopathy

Study Armgroups:
- {'label': 'Transforaminal Epidural Injection', 'type': 'EXPERIMENTAL', 'description': 'Transforaminal Epidural Injection containing 1,5 mL lidocaine 2% and 40mg methylprednisolone acetate for injections L3 or below Transforaminal Epidural Injection containing 1,5 mL lidocaine 1% and 10mg dexamethasone for injections above L3', 'interventionNames': ['Drug: Lidocaine', 'Drug: Methylprednisolone Acetate', 'Drug: Dexamethasone']}
- {'label': 'Oral pain medication', 'type': 'NO_INTERVENTION', 'description': 'Patients will receive oral pain medication according to general practitioner guidelines.'}

Interventions:
- {'type': 'DRUG', 'name': 'Lidocaine', 'description': 'In combination with dexamethasone or methylprednisolone acetate', 'armGroupLabels': ['Transforaminal Epidural Injection']}
- {'type': 'DRUG', 'name': 'Methylprednisolone Acetate', 'description': 'In combination with lidocaine', 'armGroupLabels': ['Transforaminal Epidural Injection'], 'otherNames': ['Depo-Medrol']}
- {'type': 'DRUG', 'name': 'Dexamethasone', 'description': 'In combination with lidocaine', 'armGroupLabels': ['Transforaminal Epidural Injection']}

Primary Outcomes:
- {'measure': 'Numerical Rating Scale (NRS) for leg pain', 'description': 'Pain intensity in the leg using the NRS. 0 is the minimal score indicating no pain, 10 is the maximum indicating the worst imaginable pain. Scale increases with increments of 1.', 'timeFrame': '2 weeks after randomization'}

Please estimate the sample size based on the assumption: 
Power of 90% (β = 0.10) and a significance level of 5% (α = 0.05). Estimated loss to follow-up of 10%.
Sample size
        It is hypothesized that patients in the intervention group will have a mean NRS for leg pain of 4.0 on a 11-point scale at two weeks after treatment with TEI and patients in the control group will have a mean NRS for leg pain of 5.5 two weeks after randomization. Based on literature review, a difference of 1.5 points on the NRS scale will be considered clinically relevant and a standard deviation of 2.6 is considered [12, 16]. Together with a power of 90% (Î²â=â0.10) and a level of significance of 5% (Î±â=â0.05), 64 patients per group are needed. With two study groups and an estimated loss to follow-up of 10% a total of 142 patients needs to be recruited.